David Lonard (CoRegen)

  • David Lonard U54 picture 11-7-2011
    Article

    SRC-3: CoRegen's revolutionary approach to cancer

    2023-10-06T10:52:06

    Drug Target Review’s Taylor Mixides exclusively interviews David Lonard, PhD, Chief Scientific Officer at CoRegen and Associate Professor at Baylor University, to uncover the mechanisms of SRC-3 and why it’s key to targeting cancer – and only cancer.